{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-054480","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2026-05-11T20:10:24+00:00","discovered_at":"2026-05-11T20:12:00.323223+00:00","generated_at":"2026-05-11T22:20:35.366889+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Turn Therapeutics Q1 net loss $971K; Phase 2 AD trial on track, topline mid-2026","bullets":["Cash and equivalents $11.2M as of March 31, 2026, up from $5.1M at Dec 31, 2025.","Net loss $970,972 ($0.03 basic EPS) vs $328,547 ($0.01) in Q1 2025.","G&A expenses $1.1M, R&D $109K; total op expenses $1.25M.","Avenue Capital facility provides up to $25M; initial $7M funded March 24, 2026; $18M available on milestones.","Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis; interim analysis Q2 2026, topline mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054480","json":"https://secwatch.observer/filing/0001213900-26-054480.json","markdown":"https://secwatch.observer/filing/0001213900-26-054480.md","text":"https://secwatch.observer/filing/0001213900-26-054480.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026054480/0001213900-26-054480-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026054480/ea0289856-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:20:35.366889+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cdef5ad494fe3899ecdd9dbb31472c4df489d9b7","claim":"Turn Therapeutics Inc. reported three months ended March 31, 2026 results: net income $ (970,972 ), EPS $ (0.03 ).","evidence_excerpt":"Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial results for the three months ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026054480/0001213900-26-054480-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2026"},{"label":"Net income","value":"$ (970,972 )"},{"label":"EPS","value":"$ (0.03 )"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}